Notice
UW Health recently identified and investigated a security incident regarding select patients’ information.Learn more
UW Health recently identified and investigated a security incident regarding select patients’ information.Learn more
Paul Harari, MD, is a UW Health radiation oncologist and a professor and chair of the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health.
Dr. Harari specializes in diagnosing and treating people with head and neck cancer. These include cancers of the mouth, neck and throat.
Dr. Harari understands that receiving a cancer diagnosis can be frightening. He listens carefully to his patients’ concerns and reassures them that he and his team will do everything possible to fight their cancer. He explains all treatment options and personalizes care to meet his patients’ needs and values.
When not providing direct patient care or teaching the next generation of oncologists, Dr. Harari leads research teams designing new radiation treatment techniques and radiation-drug combinations for head and neck cancer.
During his free time, Dr. Harari likes to spend as much time as possible with his family. He also enjoys biking, golfing and hiking.
One of the most difficult moments in a person’s life is receiving a cancer diagnosis. We work to be there for each patient, physically and emotionally, and help them survive.
The overall theme of Dr. Harari’s research program is to improve treatment outcome for patients with head and neck cancer (HNC). Areas of particular research emphasis include the interaction of molecular growth inhibitors combined with radiation and the use of conformal radiation treatment techniques to reduce normal tissue toxicity. Dr. Harari serves as Principal Investigator (PI) for the UW Head and Neck Cancer SPORE Grant, a $15 million effort to improve outcomes in HNC. UW is currently one of four centers in the nation with a NIH HNC SPORE Grant. Dr. Harari serves as PI for a series of national and international HNC clinical trials that have changed global practice for patients with HNC.